Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Classifica tra le azioni #4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Prezzo delle azioni
$27.18
Ultima sincronizzazione: 2026-07-31
Capitalizzazione di mercato
$3.38B
Variazione (1 giorno)
-1.41%
Variazione (1 anno)
197.05%
Paese
US
Scambia Tango Therapeutics, Inc. (TNGX)

Categoria

Healthcare
Rapporto P/S per Tango Therapeutics, Inc. (TNGX)
Rapporto P/S al October 2026 TTM: 67.14
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Tango Therapeutics, Inc., il rapporto P/S attuale (TTM) è 67.14. Alla fine del 2023, era pari a 25.63.
Storico del rapporto P/S per Tango Therapeutics, Inc. da 2019 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 67.14 737.15%
2024 8.02 -68.70%
2023 25.63 0.08%
2022 25.61 39.62%
2021 18.34 -61.56%
2020 47.71 1,179.46%
2019 3.73 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
10.02 -85.07%
US
40.55 -39.60%
US
3.96 -94.10%
AU
- -
CH
10.15 -84.89%
NL